Clinical pharmacology of topiramate: a review.
Clinical success with an antiepileptic drug (AED) depends primarily on its efficacy and tolerability. Clinicians also need to have a basic understanding of an AED's pharmacokinetic characteristics, particularly those affecting the potential for drug interactions such as hepatic enzyme inhibition or induction and protein-binding displacement. Successful treatment may be complicated by pharmacokinetic characteristics such as a short half-life, nonlinear kinetics, and active metabolites. Pharmacokinetic characteristics that make a drug easy to use may affect patient adherence. In general, newer AEDs such as topiramate (TPM) are simpler to use than traditional AEDs because they have more favorable pharmacokinetic characteristics and fewer drug interactions.
Garnett
W R
WR
Department of Pharmacy, School of Pharmacy, Medical College of Virginia Campus of Virginia Commonwealth University, Richmond 23298-0533, USA.
D000293:Adolescent; D000367:Age Factors; D000368:Aged; D000927:Anticonvulsants / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use; D001682:Biological Availability; D002648:Child; D002675:Child, Preschool; D004347:Drug Interactions; D004827:Epilepsy / Q000188:drug therapy* / Q000378:metabolism; D018565:Food-Drug Interactions; D005632:Fructose / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D006207:Half-Life; D006801:Humans; D007408:Intestinal Absorption; D010349:Patient Compliance; D010599:Pharmacokinetics; D014018:Tissue Distribution; D000077236:Topiramate
D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose